Tech Company Financing Transactions
Laverock Therapeutics Funding Round
On 6/1/2026, Laverock Therapeutics raised $3 million in funding from UK Research and Innovation and private investors.
Transaction Overview
Company Name
Announced On
6/1/2026
Transaction Type
Debt
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The new grants will support the development of Laverock's single-cell and AI powered gene-control platform, alongside pipeline expansion into additional therapeutic areas.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Incubator Building, Stevenage Bioscience Catalyst, Gunnels
Stevenage, SG1 2FX
UK
Stevenage, SG1 2FX
UK
Phone
Undisclosed
Website
Email Address
Overview
Laverock was founded around the core Gene Editing induced Gene Silencing Platform -- a step-change in RNAi technology. We fundamentally believe it unlocks the development of next-generation therapeutics through its unique and differentiated properties. We are actively developing a pipeline of GEiGS enabled ex vivo cell therapies, as well in vivo therapeutic approaches.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Venables
Chief Financial Officer
Sandy McDougall
Chief Operating Officer
Tom Payne
Chief Scientific Officer
Vlad Seitan
Chief Technical Officer
Tim Allsopp
Browse more venture capital transactions:
Prev: 6/1/2026: Flexprice venture capital transaction
Next: 6/1/2026: Endra AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs